Enhancing antibody-drug conjugate efficacy in solid tumours via modulating macrophage function

This PhD position at King’s College London focuses on the development and study of antibody-drug conjugates (ADCs), a cutting-edge approach in cancer therapy. ADCs combine the targeting ability of monoclonal antibodies with the cell-killing power of chemotherapeutic agents, offering a promising strategy for more effective and selective cancer treatment. The project will likely involve research into the design, synthesis, and evaluation of ADCs, exploring their mechanisms of action, efficacy, and potential for clinical application. Students will have the opportunity to work in a leading research environment, gaining expertise in oncology, immunotherapy, biochemistry, and drug delivery. The position is ideal for candidates interested in translational cancer research and the development of novel therapeutics. Details regarding funding, eligibility, and application procedures are not provided in the current description.